
Xultophy 100/3.6
Insulin Degludec And Liraglutide
- SKU
- 0169-2911
- Mfr
- Novo Nordisk
3 ml in 1 syringe, plastic, 5 syringe, plastic in 1 carton
$1,739.99
Price for one pack
Prescription required. Upload your prescription at checkout or email it to us after ordering. We ship once a pharmacist has checked it. How it works
6 is a combination of insulin degludec and liraglutide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 6 contains liraglutide. 5 )]. 6 is not recommended for the treatment of diabetic ketoacidosis.
- Strength
- Insulin Degludec 100 [iU]/mL, Liraglutide 3.6 mg/mL
- Unit of measure
- Per mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
Pharmacologic class
- GLP-1 Receptor AgonistEstablished class
- Glucagon-Like Peptide 1Chemical structure
- Glucagon-like Peptide-1 (GLP-1) AgonistsMechanism
- Insulin AnalogEstablished class
- InsulinChemical structure
- Brand name
- Xultophy 100/3.6
- Generic name
- Insulin Degludec And Liraglutide
- Manufacturer
- Novo Nordisk
- Product NDC (SKU)
- 0169-2911
- Active ingredients
- Insulin Degludec 100 [iU]/mL, Liraglutide 3.6 mg/mL
- Unit of measure
- Per mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- DEA schedule
- Not controlled
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- BLA
- Application number
- BLA208583
- Marketed since
- November 21, 2016
- Label revised
- October 14, 2025
| Package NDC | Description |
|---|---|
| 0169-2911-15 | 5 SYRINGE, PLASTIC in 1 CARTON (0169-2911-15) / 3 mL in 1 SYRINGE, PLASTIC |
Reading this NDC
0169-2911-15
- 01Labeler code
- Novo Nordisk
- 02Product code
- Xultophy 100/3.6, injection, solution
- 03Package code
- 5 syringe, plastic in 1 carton (0169-2911-15) / 3 ml in 1 syringe, plastic
100/3.6 is a combination product consisting of insulin degludec and liraglutide. Insulin degludec The primary activity of insulin degludec is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis.
Liraglutide Liraglutide is a GLP-1 receptor agonist that increases glucose-dependent insulin release, decreases glucagon secretion, and slows gastric emptying.
Warning: Risk of thyroid c-cell tumors
- Liraglutide, one of the components of XULTOPHY 100/3.6, causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether XULTOPHY 100/3.6 causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.
- XULTOPHY 100/3.6 is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of XULTOPHY 100/3.6 and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with XULTOPHY 100/3.6. WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning.
- Liraglutide, one of the components of XULTOPHY 100/3.6, causes thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether XULTOPHY 100/3.6 causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.
- XULTOPHY 100/3.6 is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and the symptoms of thyroid tumors.
XULTOPHY 100/3.6 is a combination of insulin degludec and liraglutide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use:
- XULTOPHY 100/3.6 contains liraglutide. Coadministration with any other product containing liraglutide or another glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.
- XULTOPHY 100/3.6 is not recommended for the treatment of diabetic ketoacidosis.
- XULTOPHY 100/3.6 has not been studied in combination with prandial insulin. XULTOPHY 100/3.6 is a combination of insulin degludec, a long-acting human insulin analog, and liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use:
- Coadministration with any other product containing liraglutide or another GLP-1 receptor agonist is not recommended.
- Not recommended for the treatment of diabetic ketoacidosis.
- Has not been studied in combination with prandial insulin.
Read before you order

Weight management · 3 min read
How GLP-1 weight-loss medicines work
Semaglutide, tirzepatide and liraglutide explained: how they reduce appetite, how quickly they work and what to expect in the first months.

Weight management · 2 min read
Managing nausea and other GLP-1 side effects
Practical ways to cope with nausea, constipation and reflux on semaglutide or tirzepatide, and the warning signs that need a doctor.

Weight management · 2 min read
Orlistat, phentermine and Contrave: the older weight-loss medicines
How orlistat, phentermine and naltrexone-bupropion work, who they suit and the side effects to know about before starting.
More in Weight Management
View all
Brand · Capsule
Alli
Orlistat 60 mg/1
- SKU
- 0135-0461
- Mfr
- Haleon US Holdings LLC
From $47.99Min. 7 packs

Brand · Capsule
Alli
Orlistat 60 mg/1
- SKU
- 71610-805
- Mfr
- Aphena Pharma Solutions - Tennessee, LLC
From $1,329.43

Brand · Tablet
Contrave Extended-Release
Naltrexone Hydrochloride 8 mg/1, Bupropion Hydrochloride 90 mg/1
- SKU
- 51267-890
- Mfr
- Nalpropion Pharmaceuticals LLC
From $199.00Min. 2 packs

Brand · Injection
Mounjaro
Tirzepatide 4.17 mg/mL
- SKU
- 0002-4052
- Mfr
- Eli Lilly and Company
From $1,454.99